BioVersys closes a CHF 24.2 million financing round for AMR products
The Swiss pharmaceutical BioVersys has raised CHF 24.2 million in a first closing of its Series C round. This first closing was significantly oversubscribed by both existing and new investors from diverse geographies. The company intends to complete the Series C investment round by the end of 2022.
The confidence of their investors and the renewed interest of established pharma and biotech companies in AMR validate the importance of the sector and the value of Bioversys’ portfolio of de-risked assets. In 2019, 1.27 million deaths were directly attributable to AMR, more than breast cancer, HIV, or malaria. These numbers have yet again demonstrated the consequences of the lack of novel AMR solutions and the urgent need to address one of the greatest threats to the healthcare systems of the modern era.
This first part of the Series C investment round, has focused on the development of novel antibacterial therapies against life-threatening infections. The funds will be deployed to conduct two of company pipeline programs’ clinical Phase II proof of concept studies and to advance a third program through preclinical toxicology.
BioVersys is a privately-held clinical stage, multi-asset company focusing on research and development of therapies for life-threatening multidrug-resistant bacterial infections and targeted microbiome modulation.
Walder Wyss advises BioVersys in connection with the Series C Financing. The corporate/m&a and venture capital team includes partners Alexander Gutmans (pictured left) and Robert von Rosen (pictured right), Karina Tschon (associate) as well as Lucas Maurer (associate).
